Saudi Journal of Ophthalmology
Volume 24, Issue 3 , Pages 69-75 , July 2010

Role of Avastin in management of central serous chorioretinopathy

Received 9 January 2010 ,Revised 13 March 2010 ,Accepted 13 March 2010.

References 

  1. Cardillo Piccolino F, Borgia L, Zinicola E, et al. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye. 1995;9:324–332
  2. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23:752–763
  3. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109(10):1834–1837
  4. Chan WM, Lam DSC, Lai TYY, et al. Choroidal vascular remodeling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at primary disease level. Br. J. Ophthalmol. 2003;87:1453–1458
  5. Chappelow AV, Marmor MF. Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy. Arch. Ophthalmol. 2000;118:1211–1215
  6. Cotticelli L, Borrelli M, D’Alessio AC, et al. Central serous chorioretinopathy and Helicobacter pylori. Eur. J. Ophthalmol. 2006;16(2):274–278
  7. El-Batarny AM, Tamersh MK, Kabeel MM, et al. Role of intravitreal bevacizumab (Avastin) in the management of chronic and recurrent central serous chorioretinopathy (CSC). Bull. Ophthalmol. Soc. Egypt. 2008;101(4):451–458
  8. Jalk AE, Jabbour N, Avila MP, et al. Pigment epithelium decompensation, clinical features and natural course. Ophthalmology. 1984;91:1544–1548
  9. Loo RH, Scott IU, Flynn HW, et al. Factors associated with reduced visual acuity during long-term follow up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24
  10. Penha FM, Aggio FB, Bonomo PP, et al. Severe retinal thermal injury after indocyanine green-mediated photothrombosis for central serous chorioretinopathy. Am. J. Ophthalmol. 2007;143(5):887–889
  11. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S, et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur. J. Ophthalmol. 2009;19(4):613–617
  12. Seong KH, Bae JH, Kim ES, et al. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica. 2009;223(5):343–347
  13. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol. Clin. North Am. 2006;19(3):335–344
  14. Stewart JM. Central serous chorioretinopathy half dose verteporfin PDT for central serous chorioretinopathy. Br. J. Ophthalmol. 2006;90:805–806(editrorial)
  15. Tewari HK, Gadia R, Kumar D, Venkatesh P, et al. Sympathetic–parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest. Ophthalmol. Vis. Sci. 2006;47(8):3474–3478
  16. Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefe’s Arch. Clin. Exp. Ophthalmol. 2008;246(9):1235–1239
  17. Wang M, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am. J. Ophthalmol. 2002;133:787–793

PII: S1319-4534(10)00045-7

doi: 10.1016/j.sjopt.2010.03.002

Saudi Journal of Ophthalmology
Volume 24, Issue 3 , Pages 69-75 , July 2010

Article Tools

* Image Usage & Resolution